Windtree Therapeutics (WINT)
(Delayed Data from NSDQ)
$9.99 USD
-1.81 (-15.34%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $10.02 +0.03 (0.30%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Windtree Therapeutics, Inc. (WINT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$7.00 | $7.00 | $7.00 | -40.68% |
Price Target
Only one analyst offered a short-term price target of $7.00 for Windtree Therapeutics, Inc. This represents a decline of 40.68% from the last closing price of $11.80.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Hold-equivalent recommendation for Windtree Therapeutics, Inc. This translates to an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 3.00 a month ago based on just one recommendation.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/WINT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 1 |
Average Target Price | $7.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 253 |
Current Quarter EPS Est: | -8.11 |